Norwegian produced prostate cancer drug makes solid U.S. debut

In June, Algeta opened a commercial production line for its new prostate cancer drug in Norway, just outside Oslo. The drug Xofigo® (formerly known as Alpharadin) has made a solid start in the U.S. and the company is waiting for European approval later this year. The stock market valuation of Algeta has hit NOK12 billion. Read more at Oslo Cancer Cluster